Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes insipidus. Current treatment recommendations.

J R Seckl1, D B Dunger

  • 1University of Edinburgh, Department of Medicine, Western General Hospital, Scotland.

Drugs
|August 1, 1992
PubMed
Summary

Cranial diabetes insipidus (DI) results from insufficient arginine vasopressin (AVP) release. Desmopressin (DDAVP) is effective intranasally, but new formulations are needed. Nephrogenic DI treatment remains challenging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contribution of local regeneration of glucocorticoids to tissue steroid pools.

The Journal of endocrinology·2023
Same author

Lipid ratios representing SCD1, FADS1, and FADS2 activities as candidate biomarkers of early growth and adiposity.

EBioMedicine·2021
Same author

Which infancy growth parameters are associated with later adiposity? The Cambridge Baby Growth Study.

Annals of human biology·2020
Same author

Maternal serum concentrations of bisphenol A and propyl paraben in early pregnancy are associated with male infant genital development.

Human reproduction (Oxford, England)·2020
Same author

The effects of gestational diabetes mellitus on fetal growth and neonatal birth measures in an African cohort.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Associations between a fetal imprinted gene allele score and late pregnancy maternal glucose concentrations.

Diabetes & metabolism·2017

Area of Science:

  • Endocrinology
  • Nephrology
  • Water Homeostasis

Background:

  • Cranial diabetes insipidus (DI) is characterized by inadequate arginine vasopressin (AVP) release.
  • Accurate diagnosis and management are critical, especially in acute settings like surgery or trauma, or in patients with impaired thirst.
  • Nephrogenic DI involves a lack of response to AVP, with limited therapeutic options.

Purpose of the Study:

  • To review the diagnosis and management of cranial and nephrogenic DI.
  • To highlight the role of desmopressin (DDAVP) in treating cranial DI.
  • To emphasize the importance of understanding water balance and electrolyte data.

Main Methods:

  • Review of current understanding of DI pathophysiology.
  • Discussion of desmopressin (DDAVP) as a therapeutic agent for cranial DI.
  • Analysis of challenges in managing nephrogenic DI.

Main Results:

  • Intranasal desmopressin (DDAVP) is an effective treatment for cranial DI.
  • Alternative desmopressin formulations (oral, transcutaneous) are being explored.
  • Water replacement is the primary therapy for nephrogenic DI due to disappointing treatment outcomes.

Conclusions:

  • Effective management of DI requires a thorough understanding of water homeostasis.
  • Desmopressin (DDAVP) offers a viable treatment for cranial DI, with potential for improved delivery methods.
  • Further research is needed for effective treatments for nephrogenic DI.

Related Experiment Videos